Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03727087 · ClinicalTrials.gov registry record
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma
A clinical trial, sponsored by Exact Sciences Corporation.
- Terminated
- Registry status
- 348
- Enrollment target
NCT03727087: Clinical Trial study, sponsored by Exact Sciences Corporation.
NCT03727087 is a clinical trial that was terminated before completion, run by Exact Sciences Corporation. The registered enrollment target is 348 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03727087 was terminated before completion, sponsored by Exact Sciences Corporation.
- TERMINATED
- Registry status
- 348 participants
- Enrollment target
Study Summary
The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
Primary Outcome
Biomarkers under evaluation include differential methylation of nucleic acids and altered expression of proteins in blood from subjects with melanoma at the pre-intervention stage.
Interventions
- OTHER Blood Sample Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2019-01-10 |
| Est. Completion | 2020-03-24 |
Why NCT03727087 stopped before completion
NCT03727087 is an observational study that tracks outcomes without assigning an intervention. The registered 348 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Blood Sample Collection is the first listed.
NCT03727087 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03727087 about?
NCT03727087 is a clinical study titled "Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma". The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
What is the current status of trial NCT03727087?
This trial is currently terminated. The enrollment target is 348 participants. The study started on 2019-01-10. Estimated completion is 2020-03-24.
What interventions are being tested in trial NCT03727087?
The interventions under investigation include: Blood Sample Collection (OTHER).
Who is sponsoring clinical trial NCT03727087?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041479 · 348 participants · Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
- NCT04530565 · 348 participants · Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- NCT05428735 · 348 participants · NA
The DRAGON 2 Trial
- NCT05787379 · 348 participants · NA
Care for Veterans Post-COVID-19
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI